The United States approved this Wednesday a treatment with synthetic antibodies developed by the Regeneron laboratory that showed effectiveness in fighting the Ebola virus.
The treatment approved by the US Food and Drug Administration (FDA) uses the same technology as an experimental one against covid-19 that President Donald Trump received after contracting the coronavirus.
According to the head of the FDA, Stephen Hahn, the approval of the treatment demonstrates its commitment “to respond to threats against health, both at home and abroad.”
Called Inmazeb, the treatment is administered intravenously and contains a cocktail of monoclonal antibodies that, once inoculated into the patient, bind to the virus to neutralize it just as the immune system does.
The clinical trials were conducted with 382 people, half of whom were treated with Inmazeb while the other half received a different drug.
Among those who were treated with Inmazeb, 33.8% died after 28 days, versus 51% of patients who received another drug.
The study was conducted in the Democratic Republic of Congo in 2018 and the results were published in the New England Journal of Medicine in 2019.
The most common treatment side effects were fever, chills, and rapid heart rate or breathing, but they are also symptoms of the Ebola virus.
The FDA clarified that patients receiving Inmazeb should avoid being vaccinated against Ebola during treatment as it can reduce the effectiveness of the vaccine.
Monoclonal antibodies are a relatively new type of treatment commonly used to fight cancer and inflammatory diseases.
Inmazeb has three types of highly effective antibodies against Ebola, discovered through the infection of genetically modified mice.
ia / la / yow / lp